Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

[Highflow priapism : diagnostic evaluation, contribution of ultrasound and recommendations].

Lavergne O, Thomas A, Andrianne R, Waltrégny D, Coppens L.

Rev Med Liege. 2016 Nov;71(11):513-516. French.

2.

[How I TREAT... A RENAL COLIC].

Lavergne O, Bonnet Q, Thomas A, Waltregny D.

Rev Med Liege. 2016 May;71(5):220-6. French.

3.

Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit.

Ayoub MA, Damian M, Gespach C, Ferrandis E, Lavergne O, De Wever O, Banères JL, Pin JP, Prévost GP.

J Biol Chem. 2009 Oct 16;284(42):29136-45. doi: 10.1074/jbc.M109.042333. Epub 2009 Jul 31.

4.

CDC25 inhibitors as anticancer agents are moving forward.

Brezak MC, Kasprzyk PG, Galcera MO, Lavergne O, Prévost GP.

Anticancer Agents Med Chem. 2008 Dec;8(8):857-62. Review.

PMID:
19075568
5.

IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.

Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, Ducommun B.

Int J Cancer. 2009 Mar 15;124(6):1449-56. doi: 10.1002/ijc.24080.

6.

Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.

Lavergne O, Fernandes AC, Bréhu L, Sidhu A, Brézak MC, Prévost G, Ducommun B, Contour-Galcera MO.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5. Epub 2005 Oct 10.

PMID:
16216500
7.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.

Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, Kasprzyk PG, Prevost GP, Ducommun B.

Mol Cancer Ther. 2005 Sep;4(9):1378-87.

8.

Synthesis of small molecule CDC25 phosphatases inhibitors.

Contour-Galcéra MO, Lavergne O, Brezak MC, Ducommun B, Prévost G.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5809-12.

PMID:
15501045
9.

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC.

Cancer Res. 2004 Jul 15;64(14):4942-9.

10.

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.

Cancer Res. 2004 May 1;64(9):3320-5.

11.

Inhibitors of the CDC25 phosphatases.

Prevost GP, Brezak MC, Goubin F, Mondesert O, Galcera MO, Quaranta M, Alby F, Lavergne O, Ducommun B.

Prog Cell Cycle Res. 2003;5:225-34. Review.

PMID:
14593717
12.

A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

Bailly C, Laine W, Baldeyrou B, Demarquay D, Huchet M, Coulomb H, Lanco C, Lavergne O, Bigg DC.

Anticancer Drug Des. 2001 Feb;16(1):27-36.

PMID:
11762642
13.

Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.

Lansiaux A, Facompré M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C.

Mol Pharmacol. 2001 Sep;60(3):450-61.

14.

Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.

Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L, Bigg DC.

Cancer Res. 2001 Apr 1;61(7):2961-7.

15.

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly C, Camara J, Bigg DC.

Anticancer Drugs. 2001 Jan;12(1):9-19.

PMID:
11272292
16.

The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.

Huchet M, Demarquay D, Coulomb H, Kasprzyk P, Carlson M, Lauer J, Lavergne O, Bigg D.

Ann N Y Acad Sci. 2000;922:303-5. No abstract available.

PMID:
11193907
17.

The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.

Demarquay D, Coulomb H, Huchet M, Lesueur-Ginot L, Camara J, Lavergne O, Bigg D.

Ann N Y Acad Sci. 2000;922:301-2. No abstract available.

PMID:
11193906
18.

Homocamptothecins: E-ring modified CPT analogues.

Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC.

Ann N Y Acad Sci. 2000;922:100-11. Review.

PMID:
11193885
19.

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, Coulomb H, Muller N, Baroggi N, Camara J, Le Breton C, Manginot E, Cazaux JB, Bigg DC.

J Med Chem. 2000 Jun 1;43(11):2285-9.

PMID:
10841808
20.

Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.

Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DC, da Costa PM, Kiss R.

Clin Cancer Res. 2000 Apr;6(4):1557-62.

21.

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, Bigg DC.

Biochemistry. 1999 Nov 23;38(47):15556-63.

PMID:
10569939
22.

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DC.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2599-602.

PMID:
10498216
23.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.

Cancer Res. 1999 Jun 15;59(12):2939-43.

24.

[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].

Lavergne O, Bigg DC.

Bull Cancer. 1998 Dec;Spec No:51-8. Review. French.

PMID:
9932086
25.

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.

Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC.

J Med Chem. 1998 Dec 31;41(27):5410-9.

PMID:
9876111
26.

Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extraction.

Pruñonosa J, Solà J, Peraire C, Pla F, Lavergne O, Obach R.

J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):388-92.

PMID:
8704947
27.

Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction.

Pruñonosa J, Parera L, Peraire C, Pla F, Lavergne O, Obach R.

J Chromatogr B Biomed Appl. 1995 Jun 23;668(2):281-90.

PMID:
7581863

Supplemental Content

Loading ...
Support Center